ISO 9001:2015 Certified WHO-GMP PCD Pharma Franchise Company in India300+ Products Monopoly Rights Pan India DistributionCall us: +91-86533 91199

Product List

Home / ARPOD-CV DRY SYP

MOXITHICS

Product Packing: 5 ML

Product Composition: Moxifloxacin 0.5% with Dexamethasone 0.1%

Product Price: MRP : 110

MOXITHICS

Moxifloxacin 0.5% + Dexamethasone 0.1% | DROP 5 ML

MOXITHICS is a Moxifloxacin 0.5% and Dexamethasone 0.1% drop formulation. Moxifloxacin is a fluoroquinolone antibacterial and Dexamethasone is a corticosteroid with anti-inflammatory activity. This combination should be used only for approved indications and under healthcare professional supervision.

Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, while Dexamethasone suppresses inflammatory responses. Because corticosteroids can mask or worsen some infections and prolonged use can cause important local adverse effects, diagnosis, duration and monitoring are especially important.

Composition

Each approved measured quantity contains:

· Moxifloxacin - 0.5%

· Dexamethasone - 0.1%

· Drop vehicle / excipients - q.s. Exact salt form, preservative system, route-specific specifications and complete excipient details must be verified from the current approved product label.

Dosage form: Drop

Pack size: 5 ml

Uses of MOXITHICS

MOXITHICS may be prescribed for selected bacterial infections accompanied by inflammation where a Moxifloxacin + Dexamethasone combination is specifically approved and clinically appropriate.

· Moxifloxacin provides antibacterial activity against susceptible bacteria

· Dexamethasone helps reduce inflammation, redness and related inflammatory symptoms

· The combination should be used only when both antibacterial and corticosteroid components are clinically justified

· It should not be used indiscriminately for viral, fungal or undiagnosed infections

Worsening pain, marked swelling, vision changes, severe irritation, hypersensitivity, discharge that persists or other significant symptoms require prompt professional assessment.

How MOXITHICS Works

MOXITHICS combines antibacterial and corticosteroid actions:

Moxifloxacin: A fluoroquinolone antibacterial that inhibits bacterial DNA gyrase and topoisomerase IV, interfering with bacterial DNA replication and repair.

Dexamethasone: A corticosteroid that reduces inflammatory mediator production and suppresses inflammatory responses.

The corticosteroid component may reduce inflammatory symptoms but can also mask progression of infection if the underlying condition is not appropriately treated.

Clinical response depends on the infection site, susceptibility of the organism, route of administration, exact dosing schedule, treatment duration and individual patient factors.

Antibacterial stewardship is important: use should be limited to appropriate bacterial indications to reduce unnecessary exposure and antimicrobial resistance.

Dosage and Direction for Use

Use MOXITHICS strictly according to the current approved product label and healthcare professional's prescription. Dose, frequency, route and treatment duration must not be inferred from the composition alone.

Wash hands before administration and avoid touching the dropper tip to fingers, skin or other surfaces to reduce contamination risk.

Use only by the route stated on the approved label. If other local medicines are prescribed at the same site, follow the healthcare professional's instructions regarding spacing and order of administration.

Do not extend corticosteroid-containing treatment beyond the prescribed duration without reassessment. Complete the antibacterial course as directed unless a healthcare professional advises otherwise.

Possible Side Effects

Possible adverse effects may include:

· Temporary local irritation, burning, stinging, discomfort or dryness

· Hypersensitivity reactions may occur; discontinue and seek medical advice for significant allergy symptoms

· Fluoroquinolone exposure may contribute to selection of non-susceptible organisms with prolonged or inappropriate use

· Prolonged corticosteroid exposure can delay healing, suppress local immune response and increase susceptibility to secondary infection; route-specific risks require monitoring

· Seek prompt medical attention for severe pain, significant swelling, marked vision changes, severe rash/allergy, worsening infection or other serious symptoms.

Any persistent or troublesome adverse effect should be discussed with a healthcare professional.

Precautions and Contraindications

· Avoid use in patients with known hypersensitivity to Moxifloxacin, other quinolones, Dexamethasone or any formulation excipient.

· Corticosteroid-containing drops should not be used for undiagnosed infections; viral or fungal disease may be worsened or masked.

· Prolonged corticosteroid use may require route-specific monitoring, including assessment for delayed healing, secondary infection and other steroid-related complications.

· If used ophthalmically, prolonged corticosteroid therapy can increase intraocular pressure and contribute to glaucoma or cataract formation in susceptible patients; monitoring may be required.

· If used ophthalmically, contact-lens use during active infection should follow professional and approved-label advice.

· Pregnancy, breastfeeding, pediatric use and patients with relevant local tissue disease or previous steroid complications require individualized professional assessment.

· Check the exact route, preservative system, salt forms, excipients, storage requirements and discard-after-opening instructions on the approved label.

· Keep out of reach of children and do not share the drop container with another person.

· Drug Interaction Considerations

· Systemic exposure from local drops may be limited, but clinically relevant interactions and additive effects can still depend on route, dose, duration and patient factors. Other corticosteroids, anti-infectives and local medicines should be reviewed by the prescriber.

· Provide the healthcare professional with a complete list of prescription medicines, OTC products and other drops being used before treatment.

Business Growth Opportunity with MOXITHICS

MOXITHICS offers pharmaceutical distributors and healthcare entrepreneurs an opportunity to add a Moxifloxacin 0.5% + Dexamethasone 0.1% 5 ml drop formulation to an appropriately licensed anti-infective and anti-inflammatory product portfolio.

Promotion must remain strictly consistent with the approved route, prescription status, indications, warnings, antimicrobial-stewardship principles, permitted claims and applicable regulations.

Key Business Advantages

· Moxifloxacin 0.5% + Dexamethasone 0.1% combination

· Antibacterial + corticosteroid anti-inflammatory product concept

· Compact drop dosage form

· Convenient 5 ml pack

· Suitable for an appropriately licensed specialty-care portfolio subject to approved route and indications

· Opportunity for ethical, prescription-focused promotion through appropriate healthcare channels

PCD Pharma Franchise Opportunity for MOXITHICS

Ethics Medinova Private Limited offers PCD Pharma Franchise opportunities for MOXITHICS in selected territories across India, subject to availability, applicable regulations and mutually agreed business terms.

Franchise partners may benefit from the company's product portfolio, promotional support, supply coordination and business assistance.

Franchise Support May Include

· Monopoly-based territory opportunities, subject to availability

· Promotional materials and visual aids consistent with approved claims

· Product information and marketing support

· Reliable supply coordination

· Access to a growing pharmaceutical product portfolio

· Professional partner assistance

Partner with Ethics Medinova to explore PCD Pharma Franchise opportunities for MOXITHICS and other quality-focused healthcare products.

Third-Party Manufacturing Support for Moxifloxacin + Dexamethasone Drops

Ethics Medinova also supports eligible businesses exploring third-party manufacturing of formulations similar to MOXITHICS under their own brand, subject to applicable drug licensing, regulatory, sterile-manufacturing and route-specific requirements.

Our third-party manufacturing support may include:

· Approved formulation and 5 ml pack configuration support, subject to regulatory feasibility

· Private-label manufacturing opportunities

· Customized packaging and branding support

· Product label and pack configuration assistance

· Manufacturing coordination through suitable licensed facilities

· Support for documentation and applicable regulatory requirements

This service may be suitable for eligible pharmaceutical companies seeking to expand an appropriately licensed sterile drop portfolio.

Frequently Asked Questions About MOXITHICS

1. What is MOXITHICS?

MOXITHICS is a 5 ml drop formulation containing Moxifloxacin 0.5% and Dexamethasone 0.1% according to the supplied product brief.

2. What does Moxifloxacin do?

Moxifloxacin is a fluoroquinolone antibacterial that inhibits bacterial DNA gyrase and topoisomerase IV and acts against susceptible bacteria.

3. What is the role of Dexamethasone?

Dexamethasone is a corticosteroid that suppresses inflammation. Because steroids can mask or worsen some infections, professional diagnosis and monitoring are important.

4. Can MOXITHICS be used for any infection?

No. It should be used only for approved conditions where a susceptible bacterial infection and corticosteroid-responsive inflammation make the combination clinically appropriate.

5. Can prolonged use cause problems?

Yes. Prolonged antibacterial use can encourage non-susceptible organisms, while prolonged corticosteroid exposure can delay healing, promote secondary infection and cause route-specific steroid complications.

6. How should MOXITHICS be used?

Use only by the route, dose, frequency and duration stated on the approved label or prescribed by a healthcare professional. Do not infer administration instructions from the composition alone.

7. Is a PCD Pharma Franchise available for MOXITHICS?

Yes. Ethics Medinova offers PCD Pharma Franchise opportunities for selected products and territories, subject to availability, applicable regulations and mutually agreed terms.

8. Can this formulation be manufactured under my own brand?

Eligible businesses interested in a similar Moxifloxacin + Dexamethasone drop may explore third-party manufacturing and private-label support with Ethics Medinova, subject to applicable licensing, sterile-manufacturing, regulatory and route-specific requirements.

Disclaimer

MOXITHICS product information in this document is for general professional and business information. The supplied product brief states Moxifloxacin 0.5% with Dexamethasone 0.1%, Drop 5 ML, but does not explicitly specify the administration route. No route has therefore been assumed as a confirmed product specification. Exact salt forms, route, approved indications, dosage, age range, prescription/regulatory status, contraindications, warnings, interactions, preservative/excipient system, sterile specifications, storage and discard-after-opening instructions must be verified against the current approved product label before manufacture, promotion, recommending, dispensing or use. Antibacterial use should follow antimicrobial-stewardship principles, and corticosteroid-containing drops require appropriate diagnosis and monitoring. This document is not a substitute for professional medical advice.

Dosage Form

Therapy Wise

MOXITHICS

MOXITHICS

Moxifloxacin 0.5% + Dexamethasone 0.1% | DROP 5 ML

Composition

Pack size: 5 ml

Worsening pain, marked swelling, vision changes, severe irritation, hypersensitivity, discharge that persists or other significant symptoms require prompt professional assessment.

The corticosteroid component may reduce inflammatory symptoms but can also mask progression of infection if the underlying condition is not appropriately treated.

Use only by the route stated on the approved label. If other local medicines are prescribed at the same site, follow the healthcare professional's instructions regarding spacing and order of administration.

· Seek prompt medical attention for severe pain, significant swelling, marked vision changes, severe rash/allergy, worsening infection or other serious symptoms.

· Keep out of reach of children and do not share the drop container with another person.

· Provide the healthcare professional with a complete list of prescription medicines, OTC products and other drops being used before treatment.

Promotion must remain strictly consistent with the approved route, prescription status, indications, warnings, antimicrobial-stewardship principles, permitted claims and applicable regulations.

· Opportunity for ethical, prescription-focused promotion through appropriate healthcare channels

Franchise partners may benefit from the company's product portfolio, promotional support, supply coordination and business assistance.

Partner with Ethics Medinova to explore PCD Pharma Franchise opportunities for MOXITHICS and other quality-focused healthcare products.

This service may be suitable for eligible pharmaceutical companies seeking to expand an appropriately licensed sterile drop portfolio.

Frequently Asked Questions About MOXITHICS

MOXITHICS is a 5 ml drop formulation containing Moxifloxacin 0.5% and Dexamethasone 0.1% according to the supplied product brief.

Moxifloxacin is a fluoroquinolone antibacterial that inhibits bacterial DNA gyrase and topoisomerase IV and acts against susceptible bacteria.

Dexamethasone is a corticosteroid that suppresses inflammation. Because steroids can mask or worsen some infections, professional diagnosis and monitoring are important.

No. It should be used only for approved conditions where a susceptible bacterial infection and corticosteroid-responsive inflammation make the combination clinically appropriate.

Yes. Prolonged antibacterial use can encourage non-susceptible organisms, while prolonged corticosteroid exposure can delay healing, promote secondary infection and cause route-specific steroid complications.

Use only by the route, dose, frequency and duration stated on the approved label or prescribed by a healthcare professional. Do not infer administration instructions from the composition alone.

Yes. Ethics Medinova offers PCD Pharma Franchise opportunities for selected products and territories, subject to availability, applicable regulations and mutually agreed terms.

Eligible businesses interested in a similar Moxifloxacin + Dexamethasone drop may explore third-party manufacturing and private-label support with Ethics Medinova, subject to applicable licensing, sterile-manufacturing, regulatory and route-specific requirements.

Dosage Form

Therapy Wise

MOXITHICS

MOXITHICS

Moxifloxacin 0.5% + Dexamethasone 0.1% | DROP 5 ML

Composition

Pack size: 5 ml

Worsening pain, marked swelling, vision changes, severe irritation, hypersensitivity, discharge that persists or other significant symptoms require prompt professional assessment.

The corticosteroid component may reduce inflammatory symptoms but can also mask progression of infection if the underlying condition is not appropriately treated.

Use only by the route stated on the approved label. If other local medicines are prescribed at the same site, follow the healthcare professional's instructions regarding spacing and order of administration.

· Seek prompt medical attention for severe pain, significant swelling, marked vision changes, severe rash/allergy, worsening infection or other serious symptoms.

· Keep out of reach of children and do not share the drop container with another person.

· Provide the healthcare professional with a complete list of prescription medicines, OTC products and other drops being used before treatment.

Promotion must remain strictly consistent with the approved route, prescription status, indications, warnings, antimicrobial-stewardship principles, permitted claims and applicable regulations.

· Opportunity for ethical, prescription-focused promotion through appropriate healthcare channels

Franchise partners may benefit from the company's product portfolio, promotional support, supply coordination and business assistance.

Partner with Ethics Medinova to explore PCD Pharma Franchise opportunities for MOXITHICS and other quality-focused healthcare products.

This service may be suitable for eligible pharmaceutical companies seeking to expand an appropriately licensed sterile drop portfolio.

Frequently Asked Questions About MOXITHICS

MOXITHICS is a 5 ml drop formulation containing Moxifloxacin 0.5% and Dexamethasone 0.1% according to the supplied product brief.

Moxifloxacin is a fluoroquinolone antibacterial that inhibits bacterial DNA gyrase and topoisomerase IV and acts against susceptible bacteria.

Dexamethasone is a corticosteroid that suppresses inflammation. Because steroids can mask or worsen some infections, professional diagnosis and monitoring are important.

No. It should be used only for approved conditions where a susceptible bacterial infection and corticosteroid-responsive inflammation make the combination clinically appropriate.

Yes. Prolonged antibacterial use can encourage non-susceptible organisms, while prolonged corticosteroid exposure can delay healing, promote secondary infection and cause route-specific steroid complications.

Use only by the route, dose, frequency and duration stated on the approved label or prescribed by a healthcare professional. Do not infer administration instructions from the composition alone.

Yes. Ethics Medinova offers PCD Pharma Franchise opportunities for selected products and territories, subject to availability, applicable regulations and mutually agreed terms.

Eligible businesses interested in a similar Moxifloxacin + Dexamethasone drop may explore third-party manufacturing and private-label support with Ethics Medinova, subject to applicable licensing, sterile-manufacturing, regulatory and route-specific requirements.

We value your privacy

Get the Product Details